Currently undergoing phase2a trials.
4 Likes
The flaw of the study is they’re testing it as an add-on to existing antipsychotics, which is not at all what we want, yes?
“A study to compare the change in symptom severity in patients with schizophrenia or related
psychotic disorder when treated with GWP42003 or placebo, added to existing anti-psychotic
therapy over a period of six weeks. Secondary objectives are to evaluate the effect of
GWP42003 on quality of life and cognition and to assess the safety and tolerability of
GWP42003.” (from ClinicalTrials.gov)
2 Likes
I am pretty sure that is what it means if you read it carefully, Either that, or the sentence is written poorly.
Yes, you’re right. Your observation bought me crashing down to earth.
At least we might be able to lower the dose of our primary antipsychotics?
So it is in phase two. How long until it is ready to be prescribed by our psychiatrists?
Apparently the same drug when used in another trial for a physical condition was not well tolerated. So maybe tolerability issues may still be on the table with CBD.
That sucks bro. In the trial they did in germany it had fewer side effects than an atypical antipsychotic, so keep in mind it is still probably a better option than what we’re taking currently as far as that goes, which have “tolerability” issues of their own.
This study showed it was well tolerated. http://jop.sagepub.com/content/20/5/683.short
Cannabidiol monotherapy for treatment-resistant schizophrenia
“All patients tolerated CBD very well and no side effects were reported.”
Keep in mind that although the results were poor in the study as far as effectiveness, the patients weren’t responding to conventional antipsychotics either.
monotherapy: the treatment of a disease with a single drug.
As for availability, it looks like 2017 at the earliest.
“More recently, CBD was administered to three 22- or 23-year-old male
patients with a diagnosis of schizophrenia who had not responded to
typical antipsychotic drugs (48). They received placebo for 5 days in
the hospital followed by CBD from the 6th to the 35th day. After
this period, they received placebo for an additional 5 days, followed
by olanzapine for at least 15 days. The dose of CBD was increased
from 40 up to 1280 mg/day. The patients were assessed by two
psychiatrists, who were blind to the doses administered, using the BPRS
and UKU scales. No side effects were observed during CBD treatment,
even at the higher dose of 1280 mg/day. A partial improvement was
observed in one patient (Figure 3, patient B) while slight or no improvement was observed in the other two (Figure 3,
patients C and D). However, the patients (C and D) were considered
to be refractory, since they did not even respond to clozapine, a
fact that may explain the lack of CBD effectiveness (48). Figure 3 shows the results obtained with the 4 schizophrenic patients treated
so far with CBD. These studies suggest, therefore, that CBD has an
antipsychotic-like profile in healthy volunteers and may possess
antipsychotic properties in schizophrenic patients, but not in the
resistant ones.” http://www.scielo.br/scielo.php?pid=s0100-879x2006000400001&script=sci_arttext
Yes, that’s not GWP42003. And it didn’t work.
Is GWP42003 a synthetic form of CBD? If so that explains it.
Otherwise what is the difference between GWP42003 and the CBD in the study?
Dosage maybe? I notice all these studies fail to mention the dose of CBD.
Experimental: 1
Drug: Cannabidiol
Capsules, 3 times daily, 200 mg, 4 weeks
Active Comparator: 2
Drug: Amisulpride
Capsules, 3 times daily, 200 mg, 4 weeks
1 Like
I’m certain that was the study where it was as effective as an antipsychotic and with fewer side effects. It hasn’t been updated since 2008, so although it looks new it is not. It is led by Markus Leweke of the University of Cologne in Germany, which is the same information in this article
Placebo Comparator: Placebo
Placebo oral solution is presented as an oily solution containing excipients, sesame oil, ethanol, sucralose and strawberry flavouring.
Dose: 5 mL Placebo oral solution to be taken twice daily for 6 weeks.
The total dose administered within any 24-hour interval will be 10 mL of oral solution.
Drug: Placebo
Patients will self-administer their allocated randomised treatment twice daily (in the morning and in the evening) for six weeks using the dosing spoons provided with each bottle. Study medication will be swallowed and may be taken with other concomitant medications, as directed by the investigator.
Other Name: Placebo control
Active Comparator: GWP42003
GWP42003 oral solution is presented as an oily solution containing 100 mg/mL of cannabidiol (CBD) dissolved in excipients, sesame oil, ethanol, sucralose and strawberry flavouring.
Dose: 5 mL GWP42003 (500 mg CBD) oral solution to be taken twice daily for 6 weeks.
The total dose administered within any 24-hour interval will be 10 mL of oral solution (1 g CBD).
Drug: GWP42003
Patients will self-administer their allocated randomised treatment twice daily (in the morning and in the evening) for six weeks using the dosing spoons provided with each bottle. Study medication will be swallowed and may be taken with other concomitant medications, as directed by the investigator.
Other Names:
Cannabidiol
Epidiolex